StrainRx - a cannabis intelligence platform for identification and location of optimally therapeutic cannabis products - is announcing the appointment of Justin Tran as the head of clinical research.
LOS ANGELES, April 17, 2019 (Newswire.com)
-
StrainRx is a cannabis intelligence platform that facilitates the identification and location of cannabis products that are ideally suited for users' complex and nuanced needs. To further the platform's expertise and understanding of the cannabis plant and its pharmacological potential, StrainRx is announcing the appointment of Justin Tran to the executive team as the head of clinical research.
We are positioned between the world of sourcing (the cultivators), and the world of academia, and as such, StrainRx has an opportunity to become a major player in guiding the future of cannabis R&D.
Alec Perelman, CEO
Justin is a clinical research professional with over 10 years of experience in all stages of the drug development life cycle. In this role, Justin will work with the team to discover, refine and develop solutions to unmet clinical needs with a global perspective.
Throughout his distinguished career, Justin has worked on concept development, patenting and technological licensing. He also has direct knowledge of the patient and provider experience. By joining StrainRx, Justin says that he is looking forward to playing a key role in the future of cannabinoid therapeutics and the creation and integration of clinical solutions using evidence-based medicine.
"We are positioned between the world of sourcing (the cultivators) and the world of academia and as such, StrainRx has an opportunity to become a major player in guiding the future of cannabis R&D," said StrainRx CEO Alec Perelman. "We're here to make a meaningful and lasting difference and I am honored to work alongside such talented individuals."
